Company intelligence / Profile preview

CIS US

Atlanta, Georgia, USAuscis.gov ↗

Ownership: Private
Employees: ~5
Development stage: Other

Overview

CIS Biotech develops rapid and inexpensive blood tests to detect markers associated with ischemic attacks or strokes. The company leverages decades of neurobiology and laboratory medicine research to create patented diagnostics that aid in early detection and management of cerebrovascular events. Their main product line consists of blood-based assays for stroke biomarkers.

Therapeutic areas: CardiovascularNeurology
Modalities: Diagnostic test (blood-based diagnostics)
Industry: Protein Biomarker Diagnostics

Beyond the preview

Go deeper on CIS US.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CIS US.

Explore the full profile